2.35
+0.02(+0.86%)
Currency In USD
| Previous Close | 2.33 |
| Open | 2.34 |
| Day High | 2.5 |
| Day Low | 2.28 |
| 52-Week High | 6.63 |
| 52-Week Low | 1.31 |
| Volume | 992,217 |
| Average Volume | 515,298 |
| Market Cap | 166.91M |
| PE | -1.61 |
| EPS | -1.46 |
| Moving Average 50 Days | 1.94 |
| Moving Average 200 Days | 2.12 |
| Change | 0.02 |
If you invested $1000 in Nkarta, Inc. (NKTX) since IPO date, it would be worth $49.06 as of August 18, 2025 at a share price of $2.35. Whereas If you bought $1000 worth of Nkarta, Inc. (NKTX) shares 3 years ago, it would be worth $138.15 as of August 18, 2025 at a share price of $2.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series
GlobeNewswire Inc.
Jul 23, 2025 12:01 PM GMT
SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the H.C. Wainwrigh
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
GlobeNewswire Inc.
Jun 06, 2025 12:52 PM GMT
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appoint
Nkarta to Participate in an April Investor Conference
GlobeNewswire Inc.
Apr 01, 2025 12:01 PM GMT
SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferenc